NASDAQ:ABSI Absci (ABSI) Stock Price, News & Analysis $9.30 +0.38 (+4.20%) As of 09:50 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Absci Stock (NASDAQ:ABSI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Absci alerts:Sign Up Key Stats Today's Range$8.90▼$9.3350-Day Range$5.94▼$11.6252-Week Range$2.24▼$12.06Volume192,957 shsAverage Volume4.53 million shsMarket Capitalization$1.45 billionP/E RatioN/ADividend YieldN/APrice Target$13.43Consensus RatingModerate Buy Company Overview Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications. The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework. By integrating AI-driven protein design with advanced screening processes, the company seeks to rapidly advance promising biologic candidates from concept through lead optimization. Absci’s platform supports research in areas such as oncology, immunology and metabolic disease, providing partners with drug-like protein candidates and data insights that can de-risk preclinical development. Founded in 2018 and headquartered in Seattle, Washington, Absci maintains collaborative relationships with multiple global pharmaceutical organizations and operates additional research facilities in the United States. The company’s leadership team brings together experts in protein engineering, data science and drug development, aiming to transform biologics discovery through technological innovation. As Absci continues to expand its pipeline partnerships and platform capabilities, it remains focused on delivering scalable solutions for the next generation of protein therapeutics.AI Generated. May Contain Errors. Read More Absci Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreABSI MarketRank™: Absci scored higher than 52% of companies evaluated by MarketBeat, and ranked 535th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAbsci has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 8 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAbsci has a consensus price target of $13.43, representing about 50.4% upside from its current price of $8.93.Amount of Analyst CoverageAbsci has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Absci's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Absci are expected to grow in the coming year, from ($0.71) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Absci is -10.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Absci is -10.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbsci has a P/B Ratio of 7.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Absci's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.63% of the float of Absci has been sold short.Short Interest Ratio / Days to CoverAbsci has a short interest ratio ("days to cover") of 7.93.Change versus previous monthShort interest in Absci has recently decreased by 3.22%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbsci does not currently pay a dividend.Dividend GrowthAbsci does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Absci this week, compared to 4 articles on an average week.Search Interest24 people have searched for ABSI on MarketBeat in the last 30 days. This is an increase of 4% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Absci to their MarketBeat watchlist in the last 30 days. This is a decrease of -11% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Absci insiders have not sold or bought any company stock.Percentage Held by Insiders10.52% of the stock of Absci is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.05% of the stock of Absci is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Absci's insider trading history. Receive ABSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Absci and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABSI Stock News HeadlinesAbsci (ABSI) Projected to Release Earnings on TuesdayAugust 10 at 2:26 AM | americanbankingnews.comAbsci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026July 14, 2026 | globenewswire.comSpaceX is NOT the #1 IPO of 2026A lesser known AI company is growing faster than both SpaceX and OpenAI. Its coding business reportedly grew from 500 million dollars to 2.5 billion dollars in just five months, and more than 300000 businesses now use its technology. While OpenAI reportedly lost 39 billion dollars last year, this company is projecting a 559 million dollar quarterly profit. Google, Amazon, Nvidia, Microsoft, Sequoia and Peter Thiel's Founders Fund have all reportedly backed it. A publicly traded backdoor may offer regular investors exposure before the expected IPO frenzy, no accredited status or brokerage minimums required.August 10 at 1:00 AM | The Oxford Club (Ad)AbSci (ABSI) Receives a Buy from H.C. WainwrightJuly 7, 2026 | theglobeandmail.comBTIG Remains a Buy on AbSci (ABSI)July 2, 2026 | theglobeandmail.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), AbSci (ABSI) and Viking Therapeutics (VKTX)June 26, 2026 | theglobeandmail.comAbsci (ABSI) Is Up 37.8% After ABS-201 Data And Equity Raise - Has The Bull Case Changed?June 26, 2026 | finance.yahoo.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD) and AbSci (ABSI)June 25, 2026 | theglobeandmail.comSee More Headlines ABSI Stock Analysis - Frequently Asked Questions How have ABSI shares performed this year? Absci's stock was trading at $3.49 at the beginning of 2026. Since then, ABSI stock has increased by 155.9% and is now trading at $8.93. How were Absci's earnings last quarter? Absci Corporation (NASDAQ:ABSI) announced its quarterly earnings data on Thursday, May, 7th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.01. The business had revenue of $0.22 million for the quarter, compared to analyst estimates of $1.39 million. Absci had a negative net margin of 6,450.76% and a negative trailing twelve-month return on equity of 66.32%. Read the conference call transcript. When did Absci IPO? Absci (ABSI) raised $200 million in an initial public offering (IPO) on Thursday, July 22nd 2021. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. Who are Absci's major shareholders? Top institutional investors of Absci include BlackRock Inc. (7.81%), Bank of New York Mellon Corp (0.25%), Deutsche Bank AG (0.09%) and Uniting Wealth Partners LLC (0.06%). Insiders that own company stock include Phoenix Venture Partners Ii Lp, Sean Mcclain, Redmile Group, Llc, Andreas Busch, Zachariah Jonasson, Todd Bedrick and Menelas N Pangalos. View institutional ownership trends. How do I buy shares of Absci? Shares of ABSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Absci own? Based on aggregate information from My MarketBeat watchlists, some other companies that Absci investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Arista Networks (ANET) and CrowdStrike (CRWD). Company Calendar Last Earnings5/07/2026Today8/10/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 ABSI's financial health is in the Green zone, according to TradeSmith. ABSI has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ABSI CIK1672688 Webwww.absci.com Phone360-949-1041FaxN/AEmployees210Year Founded2011Price Target and Rating Average Price Target for Absci$13.43 High Price Target$17.00 Low Price Target$10.00 Potential Upside/Downside+44.8%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$115.18 million Net Margins-6,450.76% Pretax Margin-6,445.81% Return on Equity-66.32% Return on Assets-57.01% Debt Debt-to-Equity RatioN/A Current Ratio6.59 Quick Ratio6.59 Sales & Book Value Annual Sales$2.80 million Price / Sales516.25 Cash FlowN/A Price / Cash FlowN/A Book Value$1.26 per share Price / Book7.36Miscellaneous Outstanding Shares155,900,000Free Float139,504,000Market Cap$1.45 billion OptionableOptionable Beta2.35 Social Links 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:ABSI) was last updated on 8/10/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredBarricks gold output fell from 2 million ounces to 719000Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...Golden Portfolio | SponsoredChina is not hedging. It's escaping.China's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...Behind the Markets | SponsoredThe ultimate IPO unicornAnthropic is now worth more than a trillion dollars, making it the first private company to reach that milesto...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredBeginner’s Guide to GoldThe Ultimate Beginner's Guide to Gold IRAs Protect Your Retirement Savings Before It's Too Late With This I...Goldco Direct, LLC | SponsoredFree Stock Pick: The Company First in Line for America’s New Super FuelThe U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Absci Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Absci With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
